Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 47Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Recurrence 1Malignant Neoplasms of Digestive Organs 1Advanced Nonhematologic Malignancies 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × MLN 8237 × Clear all
NCT02780011 2018-07-27

AD3LE

The Methodist Hospital Research Institute

Phase 1 Withdrawn

Recurrence

NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT01613261 2013-11-01

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Withdrawn

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡